Dark Streaming/Mobile Old Site Home Daily Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
16:37:33 EDT Mon 27 Mar 2023
Enter Symbol
or Name
USA
CA



News for U:LXRX from 2022-03-28 to 2023-03-27 - 34 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2023-03-04 12:00U:LXRXNews ReleaseNew Analyses of Sotagliflozin Showing Time to Clinical Benefit Presented at The American College of Cardiology ¢ € ™s 72nd Annual Scientific Session Together With World Heart Federation ¢ € ™s World Congress of Cardiology
2023-03-04 10:00U:LXRXNews ReleaseLexicon Reveals ¢ € œINTO THE DARK ¢ €  Awareness Campaign About Vulnerable and Dangerous Period of Time Faced by Heart Failure Patients Following Hospitalization
2023-03-02 16:00U:LXRXNews ReleaseLexicon Pharmaceuticals Reports Fourth Quarter 2022 Financial Results and Provides Business Update
2023-02-28 17:00U:LXRXNews ReleaseLexicon Pharmaceuticals to Host Fourth Quarter 2022 Financial Results Conference Call and Webcast on March 2, 2023
2023-02-20 08:00U:LXRXNews ReleaseNew Analyses of Sotagliflozin to Be Presented at the American College of Cardiology ¢ € ™s 72nd Annual Scientific Session Together With World Heart Federation ¢ € ™s World Congress of Cardiology
2023-01-06 16:05U:LXRXNews ReleaseLexicon Pharmaceuticals to Participate in the 41st Annual JP Morgan Healthcare Conference
2022-12-21 16:30U:LXRXNews ReleaseLexicon Announces Topline Results From Phase 2 Proof-of-Concept Study of LX9211 in Postherpetic Neuralgia
2022-11-28 08:00U:LXRXNews ReleaseLexicon Pharmaceuticals to Participate in the 34th Annual Piper Sandler Healthcare Conference and the 5th Annual Evercore ISI HealthCONx Conference
2022-11-14 16:03U:LXRXNews ReleaseLexicon ¢ € ™s LX9211 Shows Significant and Consistent Benefits in the Treatment of Painful Diabetic Neuropathy in Full Results From the Phase 2 RELIEF-DPN-1 Trial Presented at the 16th Annual Pain Therapeutics Summit
2022-11-11 08:58U:LXRXNews ReleaseLexicon Pharmaceuticals to Participate in the 13th Annual Jefferies London Healthcare Conference
2022-11-09 16:01U:LXRXNews ReleaseLexicon Pharmaceuticals Reports Third Quarter 2022 Financial Results And Provides Business Update
2022-11-08 08:58U:LXRXNews ReleaseLexicon Pharmaceuticals Highlights Oral Presentation of Final Results From the RELIEF-DPN-1 Trial of LX9211 at the 16th Annual Pain Therapeutics Summit
2022-11-06 17:29U:LXRXNews ReleaseNew Analysis of SOLOIST-WHF Results Demonstrates Sotagliflozin's Significant Effect in Reducing the Risk of Hospital Readmissions for Heart Failure
2022-11-05 10:35U:LXRXNews ReleaseNew Analysis of SCORED Trial Demonstrates Sotagliflozin's Effect on Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease
2022-11-04 08:58U:LXRXNews ReleaseLexicon Pharmaceuticals to Host Third Quarter 2022 Financial Results Conference Call and Webcast on November 9, 2022
2022-10-31 08:59U:LXRXNews ReleaseNew Analyses of Sotagliflozin From the SOLOIST-WHF and SCORED Trials in High Cardiovascular Risk Patients to be Presented at the American Heart Association Scientific Sessions 2022
2022-10-24 08:59U:LXRXNews ReleaseLexicon Pharmaceuticals Announces Oral Presentations Relating To Its LX9211 Neuropathic Pain Program At The World Brain Disorders And Neuroscience Summit 2022
2022-10-02 13:00U:LXRXNews ReleaseNew Analysis of SOLOIST-WHF Trial Underscores Sotagliflozin's Effect on Reducing Recurrent Heart Failure Events
2022-09-20 08:59U:LXRXNews ReleaseLexicon Pharmaceuticals Highlights Scientific and Medical Presentations Relating to Its Successful Phase 2 Proof-Of-Concept Study of LX9211 in Painful Diabetic Neuropathy
2022-08-22 16:05U:LXRXNews ReleaseLexicon Pharmaceuticals Highlights Publications Relating to Sotagliflozin's Differentiated Dual SGLT1 and SGLT2 Mechanism of Action and Potential Implications for Cardiovascular Disease
2022-08-05 16:59U:LXRXNews ReleaseLexicon Announces Full Exercise and Closing of Options to Purchase Additional Shares in Connection with Previously Announced Public Offering and Concurrent Private Placement
2022-08-02 16:01U:LXRXNews ReleaseLexicon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
2022-07-29 08:00U:LXRXNews ReleaseLexicon Pharmaceuticals to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 2, 2022
2022-07-28 07:00U:LXRXNews ReleaseLexicon Announces Pricing of $85.0 Million Public Offering and Concurrent Private Placement
2022-07-27 16:01U:LXRXNews ReleaseLexicon Announces Proposed Public Offering Of Common Stock
2022-07-27 07:59U:LXRXNews ReleaseLexicon Announces FDA Acceptance of New Drug Application for Sotagliflozin to Treat Heart Failure
2022-06-29 16:01U:LXRXNews ReleaseLexicon Announces Positive Top-Line Results From Phase 2 Proof-Of-Concept Study Of LX9211 In Painful Diabetic Neuropathy
2022-06-01 08:00U:LXRXNews ReleaseLexicon Pharmaceuticals to Participate in the Jefferies 2022 Healthcare Conference
2022-05-31 08:00U:LXRXNews ReleaseLexicon Resubmits New Drug Application for Sotagliflozin for the Treatment of Heart Failure
2022-05-05 06:00U:LXRXNews ReleaseLexicon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical Update
2022-04-29 08:00U:LXRXNews ReleaseLexicon Pharmaceuticals to Host First Quarter 2022 Financial Results Conference Call and Webcast on May 5, 2022
2022-04-07 08:00U:LXRXNews ReleaseLexicon Pharmaceuticals to Participate in the 21st Annual Needham Virtual Healthcare Conference
2022-04-04 08:00U:LXRXNews ReleaseLexicon Welcomes New Guidelines for the Management of Heart Failure
2022-04-02 12:15U:LXRXNews ReleaseSotagliflozin Improved Outcomes in Patients With and Without Prior Cardiovascular Disease in New Analysis Presented at the American College of Cardiology's 71st Annual Scientific Session (ACC.22)